Bristol Myers Squibb (BMY) today announced that the FDA has expanded Breyanzi's approval to include treatment of relapsed or refractory (R/R) marginal zone lymphoma in adult patients who have received at least two prior lines of systemic therapy.
The approval was based on results from MZL cohort of TRANSCEND FL, a phase 2 single-arm study that evaluated the efficacy and safety of Breyanzi in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.
According to the study findings, 95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with Breyanzi achieved a response, with 62.1% achieving a complete response and 88.6% maintaining a response at 24 months.
Marginal zone lymphoma (MZL) is a subtype of non-Hodgkin lymphoma (NHL), accounting for about 7% of all NHL cases. Most patients with MZL are diagnosed at a median age of 67 years.
Breyanzi, a CD19-directed CAR T cell therapy administered subcutaneously, is already approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma.
With the latest approval, Breyanzi becomes the only CAR T cell therapy approved by the FDA for five different cancer types, the most of any CD19-directed CAR T cell therapy.
The drug generated global sales of $747 million for the full year of 2024 and $966 million in the first nine months of 2025.
BMY shares closed Thursday's trade at $51.95 ,up 1.94%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.